Changes in Hong Kong stocks | Giant Biotech (02367) falls nearly 4%, but sales performance in the US is under pressure, management lowered its performance guidelines for this year

The Zhitong Finance App learned that Giant Biotech (02367) fell nearly 4%. As of press release, it was down 3.86% to HK$36.82, with a turnover of HK$241 million.

According to the news, CMB International released a research report saying that due to short-term pressure from the US, the bank lowered the company's 2025/26 revenue forecast to -3.5% and 13.6%. According to the report, during the “Double Eleven” period, the company's sales were under pressure, mainly due to Dabo's sales performance falling short of expectations. On the one hand, the company takes the initiative to adjust the channel strategy, and on the other hand, it also reflects the competitive pressure of the industry as a whole. However, management maintains strategic strength in the midst of changes in the industry, maintains price and consumer experience, increases the share of self-broadcast channels, and lays the foundation for long-term growth.

Bank of America Securities previously pointed out that Giants Biotech's sales were under pressure during the Double Eleven period. According to management data, sales of the Comfy brand on Tmall and Douyin fell 20% and 50% year over year, respectively. In contrast, the Collgene brand achieved positive growth during the period. The report mentioned that management lowered this year's performance guidelines, and expected revenue to remain flat or slightly lower year on year, and lowered the net profit forecast to a high single-digit decline in the year-on-year record.